{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:14:27Z","timestamp":1785798867897,"version":"3.56.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T00:00:00Z","timestamp":1662336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Medical Health Science and Technology Project of Zhejiang Provincial Health Commission","award":["No. 2019KY448"],"award-info":[{"award-number":["No. 2019KY448"]}]},{"name":"Medical Health Science and Technology Project of Zhejiang Provincial Health Commission","award":["No. 2019KY448"],"award-info":[{"award-number":["No. 2019KY448"]}]},{"name":"Project of Wenzhou Science and Technology Bureau","award":["No. Y20210219"],"award-info":[{"award-number":["No. Y20210219"]}]},{"name":"Project of Wenzhou Science and Technology Bureau","award":["No. Y20210219"],"award-info":[{"award-number":["No. Y20210219"]}]},{"name":"Clinical Scientific Research Project of Zhejiang Medical Association","award":["No. Y2017ZYC-A25"],"award-info":[{"award-number":["No. Y2017ZYC-A25"]}]},{"name":"Clinical Scientific Research Project of Zhejiang Medical Association","award":["No. Y2017ZYC-A25"],"award-info":[{"award-number":["No. Y2017ZYC-A25"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s10637-022-01268-w","type":"journal-article","created":{"date-parts":[[2022,9,5]],"date-time":"2022-09-05T08:04:10Z","timestamp":1662365050000},"page":"1206-1215","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of dual mTORC1\/2 inhibitor AZD8055 and mTORC1 inhibitor rapamycin on the metabolism of breast cancer cells using proton nuclear magnetic resonance spectroscopy metabolomics"],"prefix":"10.1007","volume":"40","author":[{"given":"Zhitao","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaolin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjiang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huamin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziye","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,5]]},"reference":[{"key":"1268_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"1268_CR2","unstructured":"World Health Organization (WHO) (2014) WHO Position Paper on Mammography Screening. https:\/\/paho.org\/hq\/dmdocuments\/2015\/WHO-ENG-Mammography-Factsheet.pdf"},{"key":"1268_CR3","doi-asserted-by":"publisher","first-page":"342","DOI":"10.7497\/j.issn.2095-3941.2015.0089","volume":"12","author":"J Lee","year":"2015","unstructured":"Lee J, Loh K, Yap Y (2015) PI3K\/Akt\/mTOR inhibitors in breast cancer. Cancer Biol Med 12:342\u2013354. https:\/\/doi.org\/10.7497\/j.issn.2095-3941.2015.0089","journal-title":"Cancer Biol Med"},{"key":"1268_CR4","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1200\/jco.2010.34.5579","volume":"30","author":"L Carey","year":"2012","unstructured":"Carey L, Rugo H, Marcom P, Mayer E, Esteva F, Ma C, Liu M, Storniolo A, Rimawi M, Forero-Torres A et al (2012) TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 30:2615\u20132623. https:\/\/doi.org\/10.1200\/jco.2010.34.5579","journal-title":"J Clin Oncol"},{"key":"1268_CR5","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","volume":"30","author":"J Mateo","year":"2019","unstructured":"Mateo J, Lord C, Serra V, Tutt A, Balma\u00f1a J, Castroviejo-Bermejo M, Cruz C, Oaknin A, Kaye S, de Bono J (2019) A decade of clinical development of PARP inhibitors in perspective. Ann Oncol 30:1437\u20131447. https:\/\/doi.org\/10.1093\/annonc\/mdz192","journal-title":"Ann Oncol"},{"key":"1268_CR6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s13045-017-0466-3","volume":"10","author":"X Hu","year":"2017","unstructured":"Hu X, Huang W, Fan M (2017) Emerging therapies for breast cancer. J Hematol Oncol 10:98. https:\/\/doi.org\/10.1186\/s13045-017-0466-3","journal-title":"J Hematol Oncol"},{"key":"1268_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2019.12.008","volume":"80","author":"D Tewari","year":"2022","unstructured":"Tewari D, Patni P, Bishayee A, Sah A, Bishayee A (2022) Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy. Semin Cancer Biol 80:1\u201317. https:\/\/doi.org\/10.1016\/j.semcancer.2019.12.008","journal-title":"Semin Cancer Biol"},{"key":"1268_CR8","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","volume":"124","author":"S Wullschleger","year":"2006","unstructured":"Wullschleger S, Loewith R, Hall M (2006) TOR signaling in growth and metabolism. Cell 124:471\u2013484. https:\/\/doi.org\/10.1016\/j.cell.2006.01.016","journal-title":"Cell"},{"key":"1268_CR9","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/bcr3039","volume":"13","author":"T Miller","year":"2011","unstructured":"Miller T, Rexer B, Garrett J, Arteaga C (2011) Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res 13:224. https:\/\/doi.org\/10.1186\/bcr3039","journal-title":"Breast Cancer Res"},{"key":"1268_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.655731","volume":"9","author":"N Deleyto-Seldas","year":"2021","unstructured":"Deleyto-Seldas N, Efeyan A (2021) The mTOR-Autophagy Axis and the Control of Metabolism. Front Cell Dev Biol 9:655731. https:\/\/doi.org\/10.3389\/fcell.2021.655731","journal-title":"Front Cell Dev Biol"},{"key":"1268_CR11","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"R Saxton","year":"2017","unstructured":"Saxton R, Sabatini D (2017) mTOR Signaling in Growth, Metabolism, and Disease. Cell 168:960\u2013976. https:\/\/doi.org\/10.1016\/j.cell.2017.02.004","journal-title":"Cell"},{"key":"1268_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13045-019-0754-1","volume":"12","author":"H Hua","year":"2019","unstructured":"Hua H, Kong Q, Zhang H, Wang J, Luo T, Jiang Y (2019) Targeting mTOR for cancer therapy. J Hematol Oncol 12:71. https:\/\/doi.org\/10.1186\/s13045-019-0754-1","journal-title":"J Hematol Oncol"},{"key":"1268_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/cr.2015.133","volume":"26","author":"Y Yin","year":"2016","unstructured":"Yin Y, Hua H, Li M, Liu S, Kong Q, Shao T, Wang J, Luo Y, Wang Q, Luo T et al (2016) mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR. Cell Res 26:46\u201365. https:\/\/doi.org\/10.1038\/cr.2015.133","journal-title":"Cell Res"},{"key":"1268_CR14","first-page":"15","volume":"7","author":"Y Zheng","year":"2015","unstructured":"Zheng Y, Jiang Y (2015) mTOR Inhibitors at a Glance. Mol Cell Pharmacol 7:15\u201320","journal-title":"Mol Cell Pharmacol"},{"key":"1268_CR15","doi-asserted-by":"publisher","first-page":"R43","DOI":"10.1530\/eje-13-0586","volume":"170","author":"B Verg\u00e8s","year":"2014","unstructured":"Verg\u00e8s B, Walter T, Cariou B (2014) Endocrine side effects of anti-cancer drugs: effects of anti-cancer targeted therapies on lipid and glucose metabolism. Eur J Endocrinol 170:R43-55. https:\/\/doi.org\/10.1530\/eje-13-0586","journal-title":"Eur J Endocrinol"},{"key":"1268_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11523-011-0167-8","volume":"6","author":"J Carew","year":"2011","unstructured":"Carew J, Kelly K, Nawrocki S (2011) Mechanisms of mTOR inhibitor resistance in cancer therapy. Target Oncol 6:17\u201327. https:\/\/doi.org\/10.1007\/s11523-011-0167-8","journal-title":"Target Oncol"},{"key":"1268_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112820","volume":"208","author":"Y Chen","year":"2020","unstructured":"Chen Y, Zhou X (2020) Research progress of mTOR inhibitors. Eur J Med Chem 208:112820. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112820","journal-title":"Eur J Med Chem"},{"key":"1268_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41419-017-0169-2","volume":"9","author":"H Li","year":"2018","unstructured":"Li H, Liu L, Chang H, Zou Z, Xing D (2018) Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer. Cell Death Dis 9:137. https:\/\/doi.org\/10.1038\/s41419-017-0169-2","journal-title":"Cell Death Dis"},{"key":"1268_CR19","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","volume":"168","author":"M Vander Heiden","year":"2017","unstructured":"Vander Heiden M, DeBerardinis R (2017) Understanding the Intersections between Metabolism and Cancer Biology. Cell 168:657\u2013669. https:\/\/doi.org\/10.1016\/j.cell.2016.12.039","journal-title":"Cell"},{"key":"1268_CR20","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.ccell.2017.04.013","volume":"31","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Kwok-Shing Ng P, Kucherlapati M, Chen F, Liu Y, Tsang Y, de Velasco G, Jeong K, Akbani R, Hadjipanayis A et al (2017) A Pan-Cancer Proteogenomic Atlas of PI3K\/AKT\/mTOR Pathway Alterations. Cancer Cell 31:820-832.e823. https:\/\/doi.org\/10.1016\/j.ccell.2017.04.013","journal-title":"Cancer Cell"},{"key":"1268_CR21","doi-asserted-by":"publisher","unstructured":"Zhang X, Lin Q, Chen J, Wei T, Li C, Zhao L, Gao H, Zheng H (2018) High Glucose-Induced Cardiomyocyte Death May Be Linked to Unbalanced Branched-Chain Amino Acids and Energy Metabolism. Molecules 23. https:\/\/doi.org\/10.3390\/molecules23040807","DOI":"10.3390\/molecules23040807"},{"key":"1268_CR22","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jmr.2009.11.012","volume":"202","author":"F Savorani","year":"2010","unstructured":"Savorani F, Tomasi G, Engelsen S (2010) icoshift: A versatile tool for the rapid alignment of 1D NMR spectra. J Magn Reson 202:190\u2013202. https:\/\/doi.org\/10.1016\/j.jmr.2009.11.012","journal-title":"J Magn Reson"},{"key":"1268_CR23","doi-asserted-by":"publisher","unstructured":"D'Amico P, Reduzzi C, Qiang W, Zhang Y, Gerratana L, Zhang Q, Davis A, Shah A, Manai M, Curigliano G, et al. (2021) Single-Cells Isolation and Molecular Analysis: Focus on HER2-Low CTCs in Metastatic Breast Cancer. Cancers 14. https:\/\/doi.org\/10.3390\/cancers14010079","DOI":"10.3390\/cancers14010079"},{"key":"1268_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1600200","volume":"2","author":"R DeBerardinis","year":"2016","unstructured":"DeBerardinis R, Chandel N (2016) Fundamentals of cancer metabolism Sci Adv 2:e1600200. https:\/\/doi.org\/10.1126\/sciadv.1600200","journal-title":"Fundamentals of cancer metabolism Sci Adv"},{"key":"1268_CR25","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1126\/science.1193494","volume":"330","author":"A Levine","year":"2010","unstructured":"Levine A, Puzio-Kuter A (2010) The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330:1340\u20131344. https:\/\/doi.org\/10.1126\/science.1193494","journal-title":"Science"},{"key":"1268_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188559","volume":"1876","author":"S Chakraborty","year":"2021","unstructured":"Chakraborty S, Balan M, Sabarwal A, Choueiri T, Pal S (2021) Metabolic reprogramming in renal cancer: Events of a metabolic disease. Biochim Biophys Acta Rev Cancer 1876:188559. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188559","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1268_CR27","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","volume":"34","author":"N Pavlova","year":"2022","unstructured":"Pavlova N, Zhu J, Thompson C (2022) The hallmarks of cancer metabolism: Still emerging. Cell Metab 34:355\u2013377. https:\/\/doi.org\/10.1016\/j.cmet.2022.01.007","journal-title":"Cell Metab"},{"key":"1268_CR28","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1111\/jcmm.16155","volume":"25","author":"S Li","year":"2021","unstructured":"Li S, Sheng J, Liu Z, Fan Y, Zhang C, Lv T, Hu S, Jin J, Yu W, Song Y (2021) Potent antitumour of the mTORC1\/2 dual inhibitor AZD2014 in docetaxel-sensitive and docetaxel-resistant castration-resistant prostate cancer cells. J Cell Mol Med 25:2436\u20132449. https:\/\/doi.org\/10.1111\/jcmm.16155","journal-title":"J Cell Mol Med"},{"key":"1268_CR29","doi-asserted-by":"publisher","first-page":"3630","DOI":"10.1158\/1078-0432.Ccr-18-2548","volume":"25","author":"Q Zhang","year":"2019","unstructured":"Zhang Q, Zhang Y, Chen Y, Qian J, Zhang X, Yu K (2019) A Novel mTORC1\/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer. Clin Cancer Res 25:3630\u20133642. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-2548","journal-title":"Clin Cancer Res"},{"key":"1268_CR30","doi-asserted-by":"publisher","unstructured":"Holloway R, Marignani P (2021) Targeting mTOR and Glycolysis in HER2-Positive Breast Cancer. Cancers (Basel) 13. https:\/\/doi.org\/10.3390\/cancers13122922","DOI":"10.3390\/cancers13122922"},{"key":"1268_CR31","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.1172\/jci129941","volume":"130","author":"M Paul","year":"2020","unstructured":"Paul M, Pan T, Pant D, Shih N, Chen Y, Harvey K, Solomon A, Lieberman D, Morrissette J, Soucier-Ernst D et al (2020) Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets. J Clin Invest 130:4252\u20134265. https:\/\/doi.org\/10.1172\/jci129941","journal-title":"J Clin Invest"},{"key":"1268_CR32","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/bcr2889","volume":"13","author":"D Holliday","year":"2011","unstructured":"Holliday D, Speirs V (2011) Choosing the right cell line for breast cancer research. Breast Cancer Res 13:215. https:\/\/doi.org\/10.1186\/bcr2889","journal-title":"Breast Cancer Res"},{"key":"1268_CR33","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/hep.29561","volume":"67","author":"P Luo","year":"2018","unstructured":"Luo P, Yin P, Hua R, Tan Y, Li Z, Qiu G, Yin Z, Xie X, Wang X, Chen W et al (2018) A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma. Hepatology 67:662\u2013675. https:\/\/doi.org\/10.1002\/hep.29561","journal-title":"Hepatology"},{"key":"1268_CR34","doi-asserted-by":"publisher","first-page":"6902","DOI":"10.1021\/ac201458n","volume":"83","author":"N Yuliana","year":"2011","unstructured":"Yuliana N, Khatib A, Verpoorte R, Choi Y (2011) Comprehensive extraction method integrated with NMR metabolomics: a new bioactivity screening method for plants, adenosine A1 receptor binding compounds in Orthosiphon stamineus Benth. Anal Chem 83:6902\u20136906. https:\/\/doi.org\/10.1021\/ac201458n","journal-title":"Anal Chem"},{"key":"1268_CR35","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.tcb.2013.11.008","volume":"24","author":"E Mills","year":"2014","unstructured":"Mills E, O\u2019Neill L (2014) Succinate: a metabolic signal in inflammation. Trends Cell Biol 24:313\u2013320. https:\/\/doi.org\/10.1016\/j.tcb.2013.11.008","journal-title":"Trends Cell Biol"},{"key":"1268_CR36","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1172\/jci69741","volume":"123","author":"J Doherty","year":"2013","unstructured":"Doherty J, Cleveland J (2013) Targeting lactate metabolism for cancer therapeutics. J Clin Invest 123:3685\u20133692. https:\/\/doi.org\/10.1172\/jci69741","journal-title":"J Clin Invest"},{"key":"1268_CR37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.matbio.2017.12.015","volume":"67","author":"S Oikari","year":"2018","unstructured":"Oikari S, Kettunen T, Tiainen S, H\u00e4yrinen J, Masarwah A, Sudah M, Sutela A, Vanninen R, Tammi M, Auvinen P (2018) UDP-sugar accumulation drives hyaluronan synthesis in breast cancer. Matrix Biol 67:63\u201374. https:\/\/doi.org\/10.1016\/j.matbio.2017.12.015","journal-title":"Matrix Biol"},{"key":"1268_CR38","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.3892\/ijo.2016.3456","volume":"48","author":"T Koguchi","year":"2016","unstructured":"Koguchi T, Tanikawa C, Mori J, Kojima Y, Matsuda K (2016) Regulation of myo-inositol biosynthesis by p53-ISYNA1 pathway. Int J Oncol 48:2415\u20132424. https:\/\/doi.org\/10.3892\/ijo.2016.3456","journal-title":"Int J Oncol"},{"key":"1268_CR39","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s11154-016-9370-3","volume":"17","author":"S Benvenga","year":"2016","unstructured":"Benvenga S, Antonelli A (2016) Inositol(s) in thyroid function, growth and autoimmunity. Rev Endocr Metab Disord 17:471\u2013484. https:\/\/doi.org\/10.1007\/s11154-016-9370-3","journal-title":"Rev Endocr Metab Disord"},{"key":"1268_CR40","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/ijc.27707","volume":"132","author":"P Auvinen","year":"2013","unstructured":"Auvinen P, Tammi R, Kosma V, Sironen R, Soini Y, Mannermaa A, Tumelius R, Uljas E, Tammi M (2013) Increased hyaluronan content and stromal cell CD44 associate with HER2 positivity and poor prognosis in human breast cancer. Int J Cancer 132:531\u2013539. https:\/\/doi.org\/10.1002\/ijc.27707","journal-title":"Int J Cancer"},{"key":"1268_CR41","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1111\/cas.15006","volume":"112","author":"Y Saito","year":"2021","unstructured":"Saito Y, Soga T (2021) Amino acid transporters as emerging therapeutic targets in cancer. Cancer Sci 112:2958\u20132965. https:\/\/doi.org\/10.1111\/cas.15006","journal-title":"Cancer Sci"},{"key":"1268_CR42","doi-asserted-by":"publisher","unstructured":"Liu C, Ji L, Hu J, Zhao Y, Johnston L, Zhang X, Ma X (2021) Functional Amino Acids and Autophagy: Diverse Signal Transduction and Application. Int J Mol Sci 22. https:\/\/doi.org\/10.3390\/ijms222111427","DOI":"10.3390\/ijms222111427"},{"key":"1268_CR43","doi-asserted-by":"publisher","first-page":"6747","DOI":"10.1038\/s41388-020-01480-z","volume":"39","author":"H Peng","year":"2020","unstructured":"Peng H, Wang Y, Luo W (2020) Multifaceted role of branched-chain amino acid metabolism in cancer. Oncogene 39:6747\u20136756. https:\/\/doi.org\/10.1038\/s41388-020-01480-z","journal-title":"Oncogene"},{"key":"1268_CR44","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jbior.2016.01.001","volume":"62","author":"R Geck","year":"2016","unstructured":"Geck R, Toker A (2016) Nonessential amino acid metabolism in breast cancer. Adv Biol Regul 62:11\u201317. https:\/\/doi.org\/10.1016\/j.jbior.2016.01.001","journal-title":"Adv Biol Regul"},{"key":"1268_CR45","doi-asserted-by":"publisher","first-page":"631","DOI":"10.3892\/ijo.2020.5100","volume":"57","author":"S Baliou","year":"2020","unstructured":"Baliou S, Kyriakopoulos A, Spandidos D, Zoumpourlis V (2020) Role of taurine, its haloamines and its lncRNA TUG1 in both inflammation and cancer progression. On the road to therapeutics? (Review). Int J Oncol 57:631\u2013664. https:\/\/doi.org\/10.3892\/ijo.2020.5100","journal-title":"Int J Oncol"},{"key":"1268_CR46","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.trecan.2017.09.001","volume":"3","author":"S Yeo","year":"2017","unstructured":"Yeo S, Guan J (2017) Breast Cancer: Multiple Subtypes within a Tumor? Trends Cancer 3:753\u2013760. https:\/\/doi.org\/10.1016\/j.trecan.2017.09.001","journal-title":"Trends Cancer"},{"key":"1268_CR47","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1172\/jci33295","volume":"117","author":"K Polyak","year":"2007","unstructured":"Polyak K (2007) Breast cancer: origins and evolution. J Clin Invest 117:3155\u20133163. https:\/\/doi.org\/10.1172\/jci33295","journal-title":"J Clin Invest"},{"key":"1268_CR48","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"C Perou","year":"2000","unstructured":"Perou C, S\u00f8rlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C, Pollack J, Ross D, Johnsen H, Akslen L et al (2000) Molecular portraits of human breast tumours. Nature 406:747\u2013752. https:\/\/doi.org\/10.1038\/35021093","journal-title":"Nature"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01268-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-022-01268-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-022-01268-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:52:31Z","timestamp":1678510351000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-022-01268-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,5]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1268"],"URL":"https:\/\/doi.org\/10.1007\/s10637-022-01268-w","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,5]]},"assertion":[{"value":"2 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"For this type of study, informed consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}